A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia  

作　　者：Jinzeng Wang Xiaoyang Li Ping Liu Yao Dai Hongming Zhu Yunxiang Zhang Min Wu Yunying Yao Mingzhu Liu Shuting Yu Fangying Jiang Shuai Wang Haoran Mu Bo Jiao Hua Yan Wen Wu Yang Shen Junming Li Shengyue Wang Ruibao Ren 

机构地区：[1]Shanghai Institute of Hematology,State Key Laboratory for Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China [2]Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China [3]Department of General Practice,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China [4]Collaborative Innovation Center of Hematology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China [5]International Center for Aging and Cancer,Hainan Medical University,Haikou,Hainan Province 571199,China

出　　处：《Signal Transduction and Targeted Therapy》2025年第1期384-393,共10页信号转导与靶向治疗(英文)

基　　金：supported by the Shanghai Science and Technology Development Funds(No.20Z11900200 to R.R.);Key Project of National Natural Science Foundation of China(No.82230088 to R.R.);National Key Research and Development Program of China(No.2019YFA0905900 to J.L.;No.2019YFA0905902 to S.W.),National Natural Science Foundation of China(No.82170147 to R.R.;No.82370157 to J.L.;No.81970134 and 82170111 to P.L.);Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research(No.2019CXJQ01 to R.R.);the Samuel Waxman Cancer Research Foundation(to R.R.).

摘　　要：Acute myeloid leukemia(AML)is an aging-related malignancy,with patients aged≥60 years old facing significantly poorer prognosis.Umbilical cord blood(UCB)has emerged as a promising source with effective anti-aging roles.Here,we conducted a prospective,phase 2,single-arm trial of UCB infusion as an adjuvant consolidation therapy in elderly AML patients(ChiCTR-OPC15006492).A total of 51 patients were enrolled(median age 66 years;range,60-75)and received two cycles of consolidation chemotherapy combined with UCB infusion.At a median follow-up of 27.3 months(range,9.3-100),the median overall survival(OS)was not yet reached and the median event-free survival(EFS)was 72.2 months(range,5.4-100).The 2-year OS and EFS rates were 76.9%and 62.8%,respectively.No acute graft-versus-host disease(aGVHD)or toxicity-related death occurred in any patient.The median times to platelet and neutrophil recovery were 11.5 days(range,6-17)and 12.2 days(range,0-21),respectively.Singlecell RNA sequencing(scRNA-seq)identified enhanced anti-tumor and anti-aging properties of UCB,manifested through activation of immune responses and telomere synthesis/maintenance.Thesefindings suggest that UCB infusion is an effective and safe postremission adjuvant therapy for elderly AML patients.This study provides evidence that anti-aging therapy may serve as a new and promising dimension in combined cancer treatment.

关 键 词：INFUSION PATIENTS ADJUVANT 

分 类 号：R73[医药卫生—肿瘤]